[Form 4] Lightbridge Corp. Insider Trading Activity

Rhea-AI Filing Summary

Sweta Chakraborty, a director of Lightbridge Corporation (LTBR), reported multiple grants totaling 50,590 shares on Form 4. The filings show grants dated 08/28/2025: a grant of 5,000 restricted stock awards (RSAs) and several performance-based restricted stock awards (PSAs) in increments (5,000; 5,000; 3,000; 2,000) that increase her beneficial ownership from 35,590 to 50,590 shares following the transactions. The RSAs vest in three equal annual installments contingent on continued service. The PSAs vest only if specified performance conditions are met and unvested PSAs will be forfeited if not vested by December 31, 2028.

Positive

• Director received equity awards increasing reported beneficial ownership to 50,590 shares.
• RSAs include time-based vesting in three equal annual installments, promoting retention.
• PSAs tie compensation to performance with a defined performance period ending 12/31/2028.

Negative

• PSAs are conditional and may be forfeited if performance targets are not met by 12/31/2028.
• Vesting contingencies delay actual ownership; the grants are not immediately liquid or transferable until vested.

Insights

Financial Analyst

TL;DR: Director received equity awards that materially increase her reported stake; vesting and performance conditions delay realization.

These equity grants raise reported beneficial ownership to 50,590 shares, reflecting compensation delivered as both time-based RSAs and performance-based PSAs. The RSAs vest in three equal annual tranches, which phases recognition and aligns retention incentives. The PSAs depend on specified performance criteria and carry a hard forfeiture date of December 31, 2028, meaning any upside is conditional and not immediate. For modeling, treat the additional shares as potential dilution until vesting and certification events occur.

Corporate Governance Expert

TL;DR: Standard director compensation through restricted stock with both service and performance conditions; governance alignment but conditional upside.

The mix of RSAs and PSAs is a common design to balance retention and performance alignment for a director. RSAs tie the director to continued service via three annual vesting installments. PSAs require achievement of performance metrics and include an explicit forfeiture timeline (12/31/2028), which strengthens pay-for-performance linkage. Documentation is clear on vesting contingencies and forfeiture mechanics; there are no reported dispositions or sales in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chakraborty Sweta

(Last) (First) (Middle)

C/O LIGHTBRIDGE CORPORATION

11710 PLAZA AMERICA DRIVE, SUITE 2000

(Street)

RESTON VA 20190

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LIGHTBRIDGE Corp [ LTBR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/28/2025		A(1)		5,000	A	$0	35,590	D
Common Stock	08/28/2025		A(2)		5,000	A	$0	40,590	D
Common Stock	08/28/2025		A(2)		5,000	A	$0	45,590	D
Common Stock	08/28/2025		A(2)		3,000	A	$0	48,590	D
Common Stock	08/28/2025		A(2)		2,000	A	$0	50,590	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock awards (RSAs). These RSAs vest in three equal installments on the first, second and third anniversaries of the date of grant, contingent on the reporting person's continued service on each such vesting date.

2. Represents a grant of performance-based restricted stock awards (PSAs). These PSAs vest subject to achievement of a specified performance condition, and at the time of certification thereof, contingent on the reporting person's continued service on the certification date. PSAs that remain unvested as of December 31, 2028 (the end of the performance period) will automatically be forfeited and cancelled without consideration.

	/s/ Larry Goldman, Attorney-in-Fact for Sweta Chakraborty	08/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for LTBR and what is their role?

The Form 4 was filed by Sweta Chakraborty, who is identified as a Director of Lightbridge Corporation (LTBR).

What transactions were reported on the Form 4 dated 08/28/2025 for LTBR?

The filing reports grants on 08/28/2025 totaling 50,590 shares after the transactions, consisting of restricted stock awards (RSAs) and performance-based restricted stock awards (PSAs).

How do the RSAs granted to the director vest?

The RSAs vest in three equal installments on the first, second and third anniversaries of the grant date, contingent on the reporting person's continued service.

What are the vesting conditions and deadline for the PSAs?

The PSAs vest only upon achievement of specified performance conditions and any PSAs unvested by December 31, 2028 will be automatically forfeited.

Did the Form 4 report any sales or dispositions by the reporting person?

No dispositions or sales are reported; all transactions in this Form 4 are acquisitions (grants) of RSAs and PSAs.